Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 7/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 6/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22465761 | 0.98 | SMN1; SMN2 (0.44) | S1PR5S1PR4S1PR1S1PR3NOTUM | |
| SCHEMBL4759542 | 0.88 | ALDH1A1 (0.50) | SMN1; SMN2CYP1A2ALDH1A1 | |
| SCHEMBL2705521 | 0.87 | L3MBTL1 (0.42) | S1PR5SMN1; SMN2LTA4H | |
| Hydrochloric Acid SCHEMBL3982674 | 0.85 | L3MBTL1 (0.45) | S1PR5SMN1; SMN2LTA4H | |
| SCHEMBL10178067 | 0.82 | — | — | |
| SCHEMBL883997 | 0.82 | SMN1; SMN2 (0.44) | S1PR5S1PR4S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL3264345 | 0.81 | CYP1A2 (0.46) | S1PR5S1PR4S1PR1S1PR3NOTUM | |
| SCHEMBL13740434 | 0.79 | SMN1; SMN2 (0.57) | S1PR5S1PR4S1PR1S1PR3NOTUM | |
| SCHEMBL13739335 | 0.79 | SMN1; SMN2 (0.57) | S1PR5S1PR4S1PR1S1PR3NOTUM | |
| SCHEMBL934458 | 0.79 | SMN1; SMN2 (0.57) | S1PR5S1PR4S1PR1S1PR3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2435411-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | Boehringer Ingelheim International GmbH (DE) | 2012-04-04 | — | — | EP | disclosed |
| WO-2010136559-A1 | 2, 4 -DIAMINOPYRIMIDINES FOR THE TREATMENT OF DISEASES CHARACTERISED BY EXCESSIVE OR ABNORMAL CELL PROLIFERATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | WO | disclosed |